These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 25771174)

  • 1. [Pharmacovigilance center --internal medicine interactions: A useful diagnostic tool].
    Rochoy M; Gautier S; Bordet R; Caron J; Launay D; Hachulla E; Hatron PY; Lambert M
    Rev Med Interne; 2015 Aug; 36(8):516-21. PubMed ID: 25771174
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of pharmacovigilance on adverse drug reactions reporting in hospitalized internal medicine patients at Saudi Arabian teaching hospital.
    Khan LM; Al-Harthi SE; Saadah OI; Al-Amoudi AB; Sulaiman MI; Ibrahim IM
    Saudi Med J; 2012 Aug; 33(8):863-8. PubMed ID: 22886119
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of adverse drug reactions: evaluation of an automatic data processing applied in oncology performed in the French Diagnosis Related Groups database.
    Quillet A; Colin O; Bourgeois N; Favrelière S; Ferru A; Boinot L; Lafay-Chebassier C; Perault-Pochat MC
    Fundam Clin Pharmacol; 2018 Apr; 32(2):227-233. PubMed ID: 29143369
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Serious adverse drug reactions with tramadol reported to the French pharmacovigilance database between 2011 and 2015].
    Moulis F; Rousseau V; Abadie D; Masmoudi K; Micallef J; Vigier C; Pierre S; Dautriche A; Montastruc F; Montastruc JL
    Therapie; 2017 Dec; 72(6):615-624. PubMed ID: 28755832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adverse drug reactions to self-medication: a study in a pharmacovigilance database.
    Berreni A; Montastruc F; Bondon-Guitton E; Rousseau V; Abadie D; Durrieu G; Chebane L; Giroud JP; Bagheri H; Montastruc JL
    Fundam Clin Pharmacol; 2015 Oct; 29(5):517-20. PubMed ID: 26215671
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Drug-induced pancreatitis. A review of French spontaneous reports].
    Chebane L; Bagheri H; Hillaire-Buys D; Géniaux H; Yahioui N; Laroche ML; Cottin J; Spreux A; Mosquet B; Pecriaux C; Bellet F; Lambert A; Montastruc JL
    Rev Med Interne; 2015 Sep; 36(9):573-8. PubMed ID: 26045335
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Is the collecting activity of regional pharmacovigilance centers influenced by regional demographic or health determinants?].
    Lam L; Desitter C; Maison P
    Therapie; 2019 Jun; 74(3):333-341. PubMed ID: 30173895
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Evaluation of the website of the Nord-Pas-de-Calais regional pharmacovigilance center].
    Rochoy M; Béné J; Messaadi N; Auffret M; Gautier S
    Therapie; 2016 Jun; 71(3):329-33. PubMed ID: 27235657
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Comparative relevance of declaration of side effects by patients and health professionals].
    Lagneau A; Vigier C; Marianna A; Serfaty R; Rocher F; Spreux A; Drici MD
    Therapie; 2017 Dec; 72(6):625-633. PubMed ID: 28780021
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adverse events induced by ceftriaxone: a 10-year review of reported cases to Iranian Pharmacovigilance Centre.
    Shalviri G; Yousefian S; Gholami K
    J Clin Pharm Ther; 2012 Aug; 37(4):448-51. PubMed ID: 22122488
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adverse drug reaction reports for cardiometabolic drugs from sub-Saharan Africa: a study in VigiBase.
    Berhe DF; Juhlin K; Star K; Beyene KG; Dheda M; Haaijer-Ruskamp FM; Taxis K; Mol PG
    Trop Med Int Health; 2015 Jun; 20(6):797-806. PubMed ID: 25704305
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Analysis of adverse reactions and pharmacovigilance research to parenterally administered shuxuening].
    Yang W; Xiang YY; Xie YM; Shen H
    Zhongguo Zhong Yao Za Zhi; 2013 Sep; 38(18):3013-8. PubMed ID: 24471322
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Using real-world healthcare data for pharmacovigilance signal detection - the experience of the EU-ADR project.
    Patadia VK; Coloma P; Schuemie MJ; Herings R; Gini R; Mazzaglia G; Picelli G; Fornari C; Pedersen L; van der Lei J; Sturkenboom M; Trifirò G;
    Expert Rev Clin Pharmacol; 2015 Jan; 8(1):95-102. PubMed ID: 25487079
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prescription sequence symmetry analysis: assessing risk, temporality, and consistency for adverse drug reactions across datasets in five countries.
    Pratt N; Chan EW; Choi NK; Kimura M; Kimura T; Kubota K; Lai EC; Man KK; Ooba N; Park BJ; Sato T; Shin JY; Wong IC; Kao Yang YH; Roughead EE
    Pharmacoepidemiol Drug Saf; 2015 Aug; 24(8):858-64. PubMed ID: 25907076
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adverse Drug Reaction (ADR) Monitoring at the Eastern Regional Pharmacovigilance Centre, Nepal.
    Rauniar GP; Panday DR
    Kathmandu Univ Med J (KUMJ); 2017 Oct.-Dec.; 15(60):296-300. PubMed ID: 30580345
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Adverse effects of calcium channels blockers used as tocolytic treatment].
    Clouqueur E; Gautier S; Vaast P; Coulon C; Deruelle P; Subtil D; Debarge V
    J Gynecol Obstet Biol Reprod (Paris); 2015 Apr; 44(4):341-56. PubMed ID: 25726253
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Triptans and serious adverse vascular events: data mining of the FDA Adverse Event Reporting System database.
    Roberto G; Piccinni C; D'Alessandro R; Poluzzi E
    Cephalalgia; 2014 Jan; 34(1):5-13. PubMed ID: 23921799
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adverse drug reactions in patients with Alzheimer's disease and related dementia in France: a national multicentre cross-sectional study.
    Laroche ML; Perault-Pochat MC; Ingrand I; Merle L; Kreft-Jais C; Castot-Villepelet A; Durrieu G; Gras V; Guy C; Jean-Pastor MJ; Jonville-Béra AP; Merlet-Chicoine I; Miremont-Salamé G; Nourhashemi F; Charmes JP;
    Pharmacoepidemiol Drug Saf; 2013 Sep; 22(9):952-60. PubMed ID: 23794320
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Skin toxicity related to Percutalgine(®): analysis of the French pharmacovigilance database].
    Remy C; Barbaud A; Lebrun-Vignes B; Perrot JL; Beyens MN; Mounier G; Marsille F; Roy M; Mismetti P; Guy C
    Ann Dermatol Venereol; 2012 May; 139(5):350-4. PubMed ID: 22578338
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety of fibrinogen concentrate: analysis of more than 27 years of pharmacovigilance data.
    Solomon C; Gröner A; Ye J; Pendrak I
    Thromb Haemost; 2015 Apr; 113(4):759-71. PubMed ID: 25502954
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.